-
-
- Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease
-
-
- This issue chosen by the Editor of Intestinal Research is the subpopulation analysis of phase 3 induction and maintenance studies about the efficacy and safety of the Ustekinumab for Crohn's disease (CD) performed by Toshifumi Hibi et al.
The phase 3 ustekinumab study about the moderate to severe CD was performed previously. It is comprised of two 8-week induction studies (UNITI-1 and UNITI-2) and 44-week randomized maintenance study (IM-UNITI). In this previous study, intravenous ustekinumab had an effect of remission induction and remission maintenance in patients who had a clinical response to induction therapy.
This issue reported the efficacy and safety of ustekinumab from the UNITI-1, UNITI-2, and IM-UNITI global studies in a Japanese subpopulation. For Japanese patients, ustekinumab was also effective as induction and maintenance treatments.
Read more about the efficacy and safety of ustekinumab in CD.
In addition to these articles, read other articles about biologic therapy in patients with CD.
Best regards,
- Related article
-
- 1. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
Hibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C. Intest Res 2017;15(4):475-486
https://doi.org/10.5217/ir.2017.15.4.475 - 2. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P. N Engl J Med 2016;375:1946-1960
https://doi.org/10.1056/NEJMoa1602773 - 3. Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
Kotze PG, Ghosh S, Bemelman WA, Panaccione R. Intest Res 2017;15(2):160-165
https://doi.org/10.5217/ir.2017.15.2.160 - 4. Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
Ji CC, Takano S. Intest Res 2017;15(2):182-186
https://doi.org/10.5217/ir.2017.15.2.182 - 5. Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
Wu KC, Ran ZH, Gao X, Chen M, Zhong J, Sheng JQ, Kamm MA, Travis S, Wallace K, Mostafa NM, Shapiro M, Li Y, Thakkar RB, Robinson AM . Intest Res 2016;14(2):152-163
https://doi.org/10.5217/ir.2016.14.2.152
